Business
Rezubio Announces $20 Million Series A Financing to Advance the Membrane-Anchored Therapeutics Platform and Company Pipeline, with Lead Program in Obesity and Diabetes
ZHUHAI, China, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rezubio, a China-based biotechnology company founded by former Merck scientists, today announced the closing of a $20 million Series A financing. Proceeds will be used to advance the company’s lead program into Phase 2 clinical development for obesity and diabetes, as well as other programs in IND-enabling stage and early preclinical stage. The financing was led by Lapam Capital, with participation from Frees Fund and Riverhead Capital. “This Seri
About this update from Merck & Company, Inc.
[{"type":"image","alt":"Rezubio Pharmaceuticals Co., Ltd","displaySize":"","headline":null,"caption":"Rezubio Pharmaceuticals Co., Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":92,"url":"https://media.zenfs.com/en/globenewswire.com/bc4792d09f561abc0c1170e8925099eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lcMWh2r8veJBgPp6efFK2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bc4792d09f561abc0c1170e8925099eb","width":300,"height":92}},"lazy":false},{"type":"text","content":"ZHUHAI, China, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rezubio, a China-based biotechnology company founded by former Merck scientists, today announced the closing of a $20 million Series A financing. Proceeds will be used to advance the company’s lead program into Phase 2 clinical development for obesity and diabetes, as well as other programs in IND-enabling stage and early preclinical stage.","length":391,"tagName":"p"},{"type":"text","content":"The financing was led by Lapam Capital, with participation from Frees Fund and Riverhead Capital.","length":97,"tagName":"p"},{"type":"text","content":"“This Series A represents an important inflection point for Rezubio,” said Yusheng Xiong, PhD, co-founder and CEO of Rezubio. “Membrane anchoring has the potential to reshape how targeted medicines are designed. Our MADD platform enables highly localized pharmacology for cell-surface targets, including GPCRs, while minimizing systemic exposure. Our gut-targeted GPCR agonist has entered clinical trials in Australia and is expected to provide a critical proof-of-concept for the platform. In parallel, an antagonist targeting a different GPCR for immune and inflammatory diseases will enter Phase 1 clinical development in early 2026.”","length":637,"tagName":"p"},{"type":"text","content":"A Novel Approach to Tissue-Selective Delivery: Membrane-Anchored Drug Design (MADD)","length":83,"tagName":"p"},{"type":"text","content":"Rezubio’s MADD platform uses a rationally engineered kinetophore to anchor pharmacophores to the epithelium of target tissues, enabling localized drug activity at the site of action. This approach is designed to deliver:","length":220,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Minimal systemic exposure, reducing the risk of off-target and dose-limiting a...